Five things for pharma marketers to know: Thursday, February 11, 2016

Five things for pharma marketers to know: Thursday, February 11, 2016

Copaxone sales fall; Mylan to acquire Swedish drugmaker; health insurers report financial losses from ACA plans

Shannon Hartley, former head of Razorfish Health, joins nonprofit

Shannon Hartley, former head of Razorfish Health, joins nonprofit

She is the first chief marketing officer for Shatterproof.

With support of FDA committee, Remicade biosimilar edges closer to market

With support of FDA committee, Remicade biosimilar edges closer to market

The FDA is set to announce its decision on the drug in April.

IPO filing reveals Cannes Lions makes $59 million in annual revenue

IPO filing reveals Cannes Lions makes $59 million in annual revenue

Lions Health, launched in 2014, generated $1.9 million in revenue last year.

Five things for pharma marketers to know: Wednesday, February 10, 2016

Five things for pharma marketers to know: Wednesday, February 10, 2016

SEC is investigating Salix Pharmaceuticals; FDA adcomm recommends approval of Remicade biosimilar; Medicare considers payment changes

Federal agencies and ad groups join forces for prediabetes campaign

Federal agencies and ad groups join forces for prediabetes campaign

The campaign targets 86 million Americans, 90% of whom aren't aware they have the condition.

Five things for pharma marketers to know: Tuesday, February 9, 2016

Five things for pharma marketers to know: Tuesday, February 9, 2016

The FDA to review biosimilar Remicade; lawmaker looks at panelists' ties to painkiller manufacturers; Novartis signs risk-sharing contracts for Entresto

Startup unveils tools to improve trial reproducibility

Startup unveils tools to improve trial reproducibility

The newly launched tools aim to reduce the time and costs of marketing new drugs by "debugging" the lab environment.

New consumer concerns harder for health brands to swallow

New consumer concerns harder for health brands to swallow

Finicky formulary committees and rising consumer cost consciousness add up to a new market dynamic for health brands. A new survey helps break it down.

Toenail fungus, IBS drugs headline pharma Super Bowl play

Toenail fungus, IBS drugs headline pharma Super Bowl play

It's the industry's biggest turnout in the Super Bowl in three years.

Email Newsletters